"Genes, BRCA2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A tumor suppressor gene (GENES, TUMOR SUPPRESSOR) located on human chromosome 13 at locus 13q12.3. Mutations in this gene predispose humans to breast and ovarian cancer. It encodes a large, nuclear protein that is an essential component of DNA repair pathways, suppressing the formation of gross chromosomal rearrangements. (from Genes Dev 2000;14(11):1400-6)
| Descriptor ID |
D024522
|
| MeSH Number(s) |
G05.360.340.024.340.375.249.105 G05.360.340.024.340.415.400.105
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Genes, BRCA2".
Below are MeSH descriptors whose meaning is more specific than "Genes, BRCA2".
This graph shows the total number of publications written about "Genes, BRCA2" by people in this website by year, and whether "Genes, BRCA2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 2 | 0 | 2 |
| 2002 | 4 | 0 | 4 |
| 2003 | 2 | 1 | 3 |
| 2004 | 3 | 0 | 3 |
| 2005 | 7 | 0 | 7 |
| 2006 | 4 | 4 | 8 |
| 2007 | 3 | 1 | 4 |
| 2008 | 7 | 1 | 8 |
| 2009 | 3 | 1 | 4 |
| 2010 | 3 | 0 | 3 |
| 2011 | 4 | 1 | 5 |
| 2012 | 4 | 3 | 7 |
| 2013 | 1 | 0 | 1 |
| 2014 | 6 | 2 | 8 |
| 2015 | 2 | 3 | 5 |
| 2016 | 5 | 2 | 7 |
| 2017 | 3 | 0 | 3 |
| 2018 | 2 | 2 | 4 |
| 2019 | 3 | 2 | 5 |
| 2021 | 1 | 1 | 2 |
| 2022 | 1 | 1 | 2 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Genes, BRCA2" by people in Profiles.
-
Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2. J Clin Oncol. 2023 Mar 20; 41(9):1703-1713.
-
Classification of BRCA2 Variants of Uncertain Significance (VUS) Using an ACMG/AMP Model Incorporating a Homology-Directed Repair (HDR) Functional Assay. Clin Cancer Res. 2022 09 01; 28(17):3742-3751.
-
Comparison of Outcomes Between BRCA Pathogenic Variant Carriers Undergoing Breast-Conserving Surgery Versus Mastectomy. Ann Surg Oncol. 2022 Aug; 29(8):4706-4713.
-
Multigene assessment of genetic risk for women for two or more breast cancers. Breast Cancer Res Treat. 2021 Aug; 188(3):759-768.
-
Mutations in BRCA1/2 and Other Panel Genes in Patients With Metastatic Breast Cancer -Association With Patient and Disease Characteristics and Effect on Prognosis. J Clin Oncol. 2021 05 20; 39(15):1619-1630.
-
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. N Engl J Med. 2019 12 19; 381(25):2403-2415.
-
A clinical guide to hereditary cancer panel testing: evaluation of gene-specific cancer associations and sensitivity of genetic testing criteria in a cohort of 165,000 high-risk patients. Genet Med. 2020 02; 22(2):407-415.
-
Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2019 07; 121(2):180-192.
-
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med. 2019 07 25; 381(4):317-327.
-
Oestrogen receptor status and survival in women with BRCA2-associated breast cancer. Br J Cancer. 2019 02; 120(4):398-403.